What is PACAP-38?
PACAP-38 is a signaling peptide used in migraine-provocation research. The selected clinical study tested whether prior CGRP-pathway treatment prevented a migraine response to a PACAP-38 challenge.
Biological role or research focus
Migraine-provocation research.
The small provocation study does not establish therapeutic benefit of PACAP-38 or a definitive clinical prevention strategy.
Role reference: PACAP38-induced migraine attacks are independent of CGRP signaling: a randomized controlled trial. · 2025 ↗
Names you may encounter
Pituitary adenylate cyclase-activating polypeptide 38 · PACAP38
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- PACAP neuropeptide form
- Research focus
- Migraine-provocation research
- Featured evidence
- Human randomized provocation study
- Source check
- October 4, 2026
Quick answers
- Is PACAP-38 FDA approved?
- No. No FDA-approved drug contains PACAP-38. Source ↗
- Is PACAP-38 safe?
- Not an approved drug. In research infusions PACAP-38 reliably causes headache, flushing and faster heart rate, and triggers migraine-like attacks in people prone to headaches. Human safety data: trials only. The Risks & interactions section below lists what is known. Read the risks ↓
- Is PACAP-38 banned in sport?
- Very likely. The 2026 World Anti-Doping Agency (WADA) Prohibited List does not name it, but it appears to fall under a banned class (S0 Non-approved substances). Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| PACAP-38 challenge after eptinezumab or placebo (2025) | Human randomized provocation study | 38 participants with migraine without aura, 19 in each pretreatment group. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized provocation study · 2025
PACAP-38 challenge after eptinezumab or placebo
What did this publication test, and what did it find?
- Population / model
- 38 participants with migraine without aura, 19 in each pretreatment group.
- Study design
- Randomized eptinezumab-versus-placebo pretreatment followed by intravenous PACAP-38 challenge.
- Main finding
- Migraine occurred in 10 of 19 versus 12 of 19 participants; the difference was not significant (P=0.74). Headache was common after the challenge.
- Limits & context
- The small provocation study does not establish therapeutic benefit of PACAP-38 or a definitive clinical prevention strategy.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
13 registered studies name PACAP-38 as an intervention; 1 is recruiting or under way, 1 has not started recruiting yet, 9 completed and 2 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 13 listed studies.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Biomarkers in Migraine. ↗
Neurology India · 2021 Mar-Apr · Journal Article, Review
VIP and PACAP. ↗
Results and problems in cell differentiation · 2010 · Journal Article, Review
PACAP-38 in Cluster Headache: A Prospective, Case-Control Study of a Potential Treatment Target. ↗
European journal of neurology · 2025 Sep · Journal Article, Observational Study
Read available full text ↗
Targeting the PACAP-38 pathway is an emerging therapeutic strategy for migraine prevention. ↗
Expert opinion on emerging drugs · 2024 Mar · Journal Article, Review
Risks & interactions
Not an approved drug. In research infusions PACAP-38 reliably causes headache, flushing and faster heart rate, and triggers migraine-like attacks in people prone to headaches.
Human use is limited to short provocation experiments designed to trigger headache under supervision. No serious adverse events occurred in one recent trial, but no safety data exist for treatment or repeated use.
It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.
Who should not use it
- People with migraine or post-traumatic headache: PACAP-38 triggered migraine-like attacks in most participants in controlled studies
Serious risks
- Migraine-like attacks in 95% of people with post-traumatic headache vs 10% after placebo in one trial
Side effects reported in studies
- headache
- migraine-like attacks
- facial flushing
- faster heart rate
- facial swelling (in people with rosacea)
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: PACAP38-induced migraine attacks: randomized controlled trial (2025) ↗ · Hypersensitivity to PACAP-38 in post-traumatic headache (2024) ↗ · Lu AG09222 on PACAP38-induced effects in healthy subjects (2023) ↗ · PACAP-38 infusion in rosacea induces flushing and facial edema (2021) ↗
Safety & what remains unknown
Provoked headache and migraine are part of the observed response and should not be omitted from a summary.
Evidence boundaries
The small provocation study does not establish therapeutic benefit of PACAP-38 or a definitive clinical prevention strategy.
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not found on FDA's 503A category 1, 2 or 3 lists (updated May 14, 2026) or the category 2 safety-risk page (updated April 22, 2026). source - World Anti-Doping Agency (2026)
- Likely prohibited under a class rule · S0 Non-approved substances
Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & identity
The paper concerns migraine biology in people with migraine without aura. It is not evidence that PACAP-38 relieves migraine.
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.
Biology & proposed mechanism
This experiment probed relationships between PACAP-associated provocation and CGRP blockade. Provoking a symptom is different from treating it with the challenge substance.
Questions worth asking
- Was PACAP-38 given as a migraine treatment?
- What material, population, and route were actually studied?
- The small provocation study does not establish therapeutic benefit of PACAP-38 or a definitive clinical prevention strategy.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Was PACAP-38 given as a migraine treatment?
No. It was used to provoke a response while investigators tested a separate pretreatment.
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
